Sep 09, 2021 / 02:40PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Okay. Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. Welcome to the panel on Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy. And it's my great pleasure to have with me today from Atara Bio, Pascal Touchon, who's the President and CEO; from Caribou Biosciences that recently went public, Rachel Haurwitz, President and CEO; from Cellectis, Andre Choulika, the CEO; and from Gracell Bio, William Cao, the Chairman and CEO. So welcome all of you today. Thank you very much for taking the time.
Questions and Answers:
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - DirectorI think as a starting point for those less familiar with each of your companies, maybe we could just go through and do a brief introduction to the company and the pipeline and maybe comment as well on what you see as the strengths and differentiating qualities of your cell therapy platform. So maybe, Andre, you want to kick